title: [Efficacy and safety of Longjintonglin Capsule for the treatment of type III prostatitis].
abstract: OBJECTIVE
  To study the therapeutic effect and safety of Longjintonglin Capsule in the treatment of type III prostatitis (chronic prostatitis/chronic pelvic pain syndrome, CP/CPPS).
  
  
  METHODS
  We selected 240 patients with type III prostatitis according to the diagnostic standards of the American National Institute of Health (NIH) and treated them with Longjintonglin Capsule orally 3 capsules once tid for 12 weeks. Based on the NIH chronic prostatitis symptom index (NIH-CPSI), traditional Chinese medicine (TCM) syndrome score, and leukocyte count in the expressed prostatic secretion (EPS), we evaluated the results of treatment.
  
  
  RESULTS
  Totally 238 patients completed the treatment, including 108 IIIA and 120 III B prostatitis cases. Before and after 4, 8, and 12 weeks of treatment, the total NIH-CPSI scores were 23.12 ± 6.99, 18.22 ± 6.39, 14.12 ± 5.88, and 12.36 ± 6.04 (P < 0.01) in the IIIA prostatitis patients and 22.01 ± 6.28, 17.56 ± 5.89, 13.67 ± 5.18, and 11.45 ± 5.22 in the III prostatitis patients (P < 0.01), the TCM syndrome scores were 52.12 ± 13.08, 48.13 ± 12.11, 43.05 ± 11.19, and 40.78 ± 10. 59 in the former (P < 0.01) and 53.02 ± 12.12, 49.32 ± 12.78, 44.01 ± 11.79, and 39.67 ± 10.26 in the latter (P < 0.01), and the leukocyte counts were 26.09 ± 21.55, 23.02 ± 18.61, 18.25 ± 17.79, and 15.36 ± 16.38 in the IIIA cases (P < 0.01). Neither abnormalities in liver and renal function nor obvious adverse events were observed during the experiment.
  
  
  CONCLUSIONS
  Longjintonglin Capsule, with its advantages of safety, effectiveness, and no obvious adverse reactions in the treatment of type III prostatitis, deserves to be recommended for clinical application.
authors.affiliation: Department of Andrology, Jinling Hospital affiliated to Nanjing University/Nanjing General Hospital of Nanjing Military Region, Jiangsu, China. shangxj@androl.cn
authors.forename: Xue-Jun
authors.initials: XJ
authors.lastname: Shang
authors.forename: Qiang
authors.initials: Q
authors.lastname: Geng
authors.forename: Jian-Min
authors.initials: JM
authors.lastname: Duan
authors.forename: De-Quan
authors.initials: DQ
authors.lastname: Zheng
authors.forename: Lei
authors.initials: L
authors.lastname: Xie
authors.forename: Jun
authors.initials: J
authors.lastname: Guo
mesh_terms: D000284:Administration, Oral; D000328:Adult; D002214:Capsules; D059350:Chronic Pain / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017699:Pelvic Pain / Q000188:drug therapy*; D008517:Phytotherapy; D011472:Prostatitis / Q000188:drug therapy*; D013577:Syndrome
chemical_list: D002214:Capsules; D004365:Drugs, Chinese Herbal